Does altered glucocorticoid homeostasis increase cardiovascular risk?

被引:150
作者
Girod, JP [1 ]
Brotman, DJ [1 ]
机构
[1] Cleveland Clin Fdn, Dept Gen Internal Med S70, Hosp Med Fellowship, Cleveland, OH 44195 USA
关键词
hypothalamic-pituitary-adrenal axis; glucocorticoids; metabolic syndrome; stress response;
D O I
10.1016/j.cardiores.2004.07.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The hypothalamic-pituitary-adrenal (HPA) axis, like the sympathetic nervous system and the renin-angiotensin-aldosterone (RAA) system, sustains life in stressful situations by increasing vascular tone and ensuring fuel availability. It also modulates inflammation and tissue repair processes. Untoward cardiovascular effects of chronic sympathetic and RAA activation are well recognized, illustrating that the short-term benefit of the physiologic stress response can be detrimental in the long term. Similarly, chronic tissue exposure to glucocorticoids may lead to metabolic and vascular changes that accelerate vascular senescence. Specific situations associated with chronic activation of the HPA axis-such as major depression, inflammatory disease and perhaps the metabolic syndrome-may derive some of their associated cardiovascular risk from untoward glucocorticoid effects. Since there are no definitive clinical studies directly addressing the relationship between the HPA axis and cardiovascular disease, we present indirect evidence from two types of studies: (1) studies that examine the cardiovascular effects of exogenous glucocorticoids, and (2) studies demonstrating that endogenous glucocorticoid activity varies between individuals. The effects of physiologic increases in endogenous glucocorticoid activity may not always mirror the effects of supraphysiologic glucocorticoids. Nevertheless, the known effects of exogenous glucocorticoids provide important insights into the putative effects of endogenous glucocorticoids. (C) 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:217 / 226
页数:10
相关论文
共 142 条
[1]  
Abrams Jonathan, 1997, American Journal of Cardiology, V79, P2
[2]   Hydrocortisone suppresses intranuclear activator-protein-1 (AP-1) binding activity in mononuclear cells and plasma matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9) [J].
Aljada, A ;
Ghanim, H ;
Mohanty, P ;
Hofmeyer, D ;
Tripathy, D ;
Dandona, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) :5988-5991
[3]   The timing of glucocorticoid administration in rheumatoid arthritis [J].
Arvidson, NG ;
Gudbjornsson, B ;
Larsson, A ;
Hallgren, R .
ANNALS OF THE RHEUMATIC DISEASES, 1997, 56 (01) :27-31
[4]   Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells [J].
Aubert, J ;
Darimont, C ;
Safonova, I ;
Ailhaud, G ;
Negrel, R .
BIOCHEMICAL JOURNAL, 1997, 328 :701-706
[5]  
Bae J H, 2001, J Cardiol, V37 Suppl 1, P89
[6]   The balance between glucocorticoids and insulin regulates muscle proteolysis via the ubiquitin-proteasome pathway [J].
Bailey, JL ;
Wang, XN ;
Price, SR .
MINERAL AND ELECTROLYTE METABOLISM, 1999, 25 (4-6) :220-223
[7]   Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids [J].
Bamberger, CM ;
Schulte, HM ;
Chrousos, GP .
ENDOCRINE REVIEWS, 1996, 17 (03) :245-261
[8]   DIRECT EFFECTS OF CORTICOTROPIN ON PLASMA-LIPOPROTEIN METABOLISM IN MAN - STUDIES IN-VIVO AND IN-VITRO [J].
BERG, AL ;
NILSSONEHLE, P .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1994, 43 (01) :90-97
[9]   Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity [J].
Berger, J ;
Tanen, M ;
Elbrecht, A ;
Hermanowski-Vosatka, A ;
Moller, DE ;
Wright, SD ;
Thieringer, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) :12629-12635
[10]   Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus [J].
Björntorp, P ;
Holm, G ;
Rosmond, R .
DIABETIC MEDICINE, 1999, 16 (05) :373-383